Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 13, 2023 13:00 ET | Source: DelveInsight Business Research LLP

Interstitial Cystitis Market to Accelerate Substantially by 2032, Predicts DelveInsight | Leading Companies - Integrative Therapeutics, Lipella Pharmaceuticals, Allergan, Ironwood Pharmaceuticals, Vaneltix Pharma, Prevail Infoworks

New York, USA, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Interstitial Cystitis Market to Accelerate Substantially by 2032, Predicts DelveInsight | Leading Companies - Integrative Therapeutics, Lipella...
October 11, 2022 10:17 ET | Source: Data Bridge Market Research

Interstitial Cystitis Market to Receive Healthy Growth of USD 2,377.87 Million by 2029, Size, Share, Competitive Landscape, Regional Overview and Global Forecast

BOSTON, Oct. 11, 2022 (GLOBE NEWSWIRE) -- “Global Interstitial Cystitis Market” the new research report adds to Data Bridge Market Research’s reports database. This Research Report is spread across...
October 23, 2019 07:30 ET | Source: Harrow Health, Inc.

Solas BioVentures Co-Founder David Adair, M.D. Joins Mayfield Pharmaceuticals Board of Directors

BOSTON, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced David Adair, M.D. will join the...
October 08, 2019 07:35 ET | Source: Harrow Health, Inc.

Mayfield Pharmaceuticals to Present at the SVB Leerink New Treatments Focused on Women’s Health Conference on October 10, 2019

BOSTON, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced its Chief Executive Officer, Melissa...
July 31, 2019 07:30 ET | Source: Harrow Health, Inc.

Harrow Health Announces Launch of Mayfield Pharmaceuticals

NASHVILLE, Tenn., July 31, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), today announced it has filed a Form 8-K with the Securities and Exchange Commission containing a corporate...
January 28, 2016 09:15 ET | Source: Neoleukin Therapeutics, Inc.

Aquinox to Present at LEERINK Partners 5th Annual Global Healthcare Conference

VANCOUVER, British Columbia, Jan. 28, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted...
January 11, 2016 07:00 ET | Source: Neoleukin Therapeutics, Inc.

Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA

VANCOUVER, British Columbia, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted...
March 12, 2014 12:58 ET | Source: Neoleukin Therapeutics, Inc.

Aquinox Pharmaceuticals Announces Closing of Initial Public Offering

VANCOUVER, British Columbia, March 12, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (Nasdaq:AQXP) announced today the closing of its initial public offering of 4,830,000 shares of its...
March 07, 2014 09:00 ET | Source: Neoleukin Therapeutics, Inc.

Aquinox Pharmaceuticals Prices Initial Public Offering

VANCOUVER, British Columbia, March 7, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. announced today the pricing of its initial public offering of 4,200,000 shares of its common stock at a...